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Introduction: Indacaterol is a novel once daily long-acting beta agonist (LABA) developed 
for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Aims: This review summarizes preclinical and clinical data of indacaterol, including all data 
generated during the phase II trial program, and further discusses the outlook and potential of 
the drug in the future treatment of COPD and asthma.
Evidence review: Clinical studies suggest that indacaterol produces rapid and sustained bron-
chodilation in COPD patients and asthmatics of different severities. Until now, clinical studies 
of up to 28 days’ duration have been published that have confirmed the suitability of indacaterol 
for once daily dosing, along with a favorable overall safety and tolerability profile.
Outcomes summary: Indacaterol monotherapy has potential in COPD, where antiinflam-
matory treatment is not fully established and issues about a potential risk of LABA use causing 
excess mortality have not been raised. In addition, indacaterol represents an option for future 
combination therapies in both asthma and COPD. However, more data are required, particularly 
in COPD, to fully assess the therapeutic potential of indacaterol in improving symptoms, quality 
of life, exacerbation rates, disease progression, exercise capacity, and hyperinflation. The cur-
rently ongoing phase III clinical trial program will add knowledge in respect to many long-term 
efficacy outcomes and gather further safety and tolerability data in both asthma and COPD.
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Core evidence outcomes summary for indacaterol in COPD and asthma
Outcome measure Evidence Implications
Patient-oriented evidence
Tolerability Clear Overall incidence of adverse events similar to 
placebo and no dose-related increase in incidence
Favorable tolerability profile and a wide 
therapeutic window
Disease-oriented evidence
FEv1 Clear Sustained and rapid improvement in lung func-
tion comparable to salbutamol and formoterol
FvC Clear Sustained and rapid improvement in lung func-
tion comparable to salbutamol and formoterol
inspiratory capacitya Moderate Prolonged airway patency through sustained 
bronchodilation, which is an important factor 
reinforcing lung emptying and reduction of 
hyperinflation in COPD
Note: aCOPD patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEv1, forced expiratory volume in 1 s; FvC, forced 
vital capacity.Core Evidence 2009:4 38
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Introduction
An important step in simplifying the management of chronic 
airway diseases like asthma and chronic obstructive pul-
monary disease (COPD) and improving the adherence with 
prescribed therapy is the attempt to reduce dose frequency 
to the minimum needed to maintain disease control. The 
incorporation of once daily dosing may represent a useful 
strategy to improve compliance and is also a regimen that 
may be preferred by most affected patients.1
Inhaled beta2 adrenoceptor agonists are the most effec-
tive bronchodilators for the management of asthma. The 
Global Initiative for Asthma (GINA) guidelines recognize 
the role of long-acting beta2 agonists (LABAs) for the 
optimal treatment of moderate-to-severe persistent asthma.2 
Currently available inhaled LABAs have durations of 
action of approximately 12 hours at recommended doses, 
necessitating twice daily dosing to provide optimal clini-
cal efficacy.3 The availability of a once daily beta2 agonist 
could be expected to improve the treatment of asthma by 
providing patients with greater convenience and sustained 
benefit.
Current therapy options
COPD is characterized by a progressive decline in lung 
function, however, current guidelines emphasize that the 
condition is both preventable and treatable. Bronchodila-
tors are the cornerstone of treatment for all COPD severity 
stages. In more pronounced stages of airflow obstruction, 
the regular use of one or more long-acting bronchodilators 
is recommended.4 These agents include the twice daily 
beta2 agonists, formoterol and salmeterol, and the once 
daily anticholinergic, tiotropium. Long-acting broncho-
dilators may improve exercise tolerance5–7 as a result of 
bronchodilation and reduction of both static and dynamic 
hyperinflation. Once daily anticholinergics have also been 
shown to produce clinically superior effects when compared 
to short-acting agents with multiple daily doses.8 A single 
head-to-head comparison of the once daily bronchodilator 
tiotropium with twice daily salmeterol also indicates supe-
rior bronchodilation after 6 months of treatment.9 Thus, it 
appears valid to speculate that a once daily beta2 agonist 
as compared to twice daily agents will produce greater 
long-term benefit.
Indacaterol is a novel once daily beta2 adrenoceptor 
agonist developed for the treatment of asthma and COPD. 
This review will give a summary of preclinical and clinical 
data including all data generated during the phase II clinical 
development.
Pharmacology and preclinical data
Indacaterol is a beta2 agonist bronchodilator in development 
for the treatment of asthma and COPD. Indacaterol is an 
almost full beta2 agonist with high intrinsic efficacy. Unlike 
partial agonists, it does not exhibit antagonistic behaviour in 
the presence of isoprenaline.10 Potency and intrinsic efficacy 
have been demonstrated in various models including recom-
binant receptors,11 guinea pig trachea,11 isolated human 
bronchus,10 and human lung slices,12 with a selectivity 
ratio for indacaterol of 28 and 22 against beta1 and beta3 
receptors.11 In these studies, a fast onset of action and longer 
duration of action versus formoterol and salmeterol was also 
demonstrated. Pharmacokinetic data taken during multiple-
dose studies of indacaterol 400 or 800 mcg once daily for 
14 days demonstrated rapid absorption and a mean elimination 
half life of 30 hours.13 Likewise, in a single-dose study, 
doses between 600 and 2000 mcg were rapidly absorbed with 
maximum serum concentrations reached within 15 min.14 All 
doses were well tolerated with a good safety profile, and were 
not associated with consistent or clinically relevant effects on 
systemic beta agonist mediated events.
Clinical data
At the time of writing, more than 1700 patients with asthma 
or COPD have received indacaterol in various doses for up 
to 28 days of treatment during the phase II program.
Efficacy
In both asthma and COPD, single doses of indacaterol 
produced significant and sustained 24-hour bronchodilation, 
with regard to trough forced expiratory volume in 1 s (FEV1) 
and forced vital capacity (FVC). In a study by Beeh et al15 
in asthmatics, the mean percentage increases in FEV1 versus 
placebo with indacaterol 200 and 400 mcg delivered from a 
metered-dose inhaler (MDI) were, respectively, 7.6% and 
14.9% at 30 min, and 7.5% and 10.4% at 21 hours postdose. 
Both doses were significantly superior to placebo in improving 
FEV1 from 5 min to 25 hours, inclusively. These results were 
also confirmed in a subset of persistent asthmatics, where 
indacaterol 200 and 400 mcg increased FEV1 by 0.17 L at 
5 min (400 mcg) and 0.21 L at 10 min (200 mcg) compared 
with placebo.16 Hence, early studies indicated that indacaterol 
not only had a long duration of action, but also a rapid onset 
comparable to that of salbutamol or formoterol.
In a 7-day dose-ranging study,17 all doses of indacaterol 
(50, 100, 200, 400 mcg) either as a multiple-dose dry powder 
inhaler (MDDPI) or a single-dose dry powder inhaler 
(SDDPI) produced significant bronchodilation over placebo Core Evidence 2009:4 39
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at 22–24 hours postinhalation on days 1 and 7, respectively. 
Significant effects for all doses were already demonstrable 
at 5 min postdose on day 1. Of the doses evaluated, 200 mcg 
once daily appeared to be optimum as shown by trough FEV1 
24 hours postdose on days 1 and 7. This was further supported 
by a multiple-dose, dose-ranging study by Kanniess et al18 
and a 28-day safety study by Chuchalin et al.19 Finally, 
indacaterol 200 mcg was also superior to salbutamol 200 mcg 
and salmeterol 50 mcg in a single-dose study in persistent 
asthmatics20 Peak bronchodilation in these studies was 
observed between 2–4 hours postdose.
While indacaterol at different doses appears to produce 
effective bronchodilation in asthmatics, the further develop-
ment of this drug for asthma was somewhat overshadowed 
by the renewed discussion about the long-term safety of 
LABAs in asthma, since published studies suggested an 
excess incidence of asthma-related mortality associated with 
the use of this class of drugs,21,22 in particular when used as 
monotherapy. Although these findings have been criticized 
and debated,23 the use of LABAs as monotherapy is neverthe-
less not recommended in current asthma guidelines, where 
this class of agent should only be prescribed together with an 
antiinflammatory agent, preferably an inhaled corticosteroid. 
Thus, the future of indacaterol as monotherapy for asthma 
remains questionable. However, when combined with a once 
daily inhaled corticosteroid (eg, mometasone) in a fixed-dose 
inhaler combination, such a product could considerably 
improve the current treatment options for asthma by at least 
improving therapy adherence and simplicity.
COPD
Whereas the use of indacaterol monotherapy in asthma may 
be limited, there is clearly a sound rationale for its use in 
COPD, where guidelines recommend long-acting broncho-
dilators as first-line agents for patients with moderate, severe, 
and very severe disease stage. Thus, it is expected that the 
clinical development of indacaterol will have a strong focus 
on COPD.
Published data suggest that single doses of indacaterol 
produce rapid and sustained bronchodilation in patients 
with moderate to severe COPD. Rennard et al24 conducted 
a dose-ranging study of once daily indacaterol 50, 100, 200, 
and 400 mcg for 7 days in COPD patients (prebronchodilator 
FEV1  40% of predicted). While on day 1 both indacaterol 
200 and 400 mcg improved FEV1 by more than 120 mL (sug-
gested as the minimal clinically important difference), all 
doses of indacaterol were superior to placebo on day 7, with 
trough FEV1 values of 160–230 mL versus placebo. There 
was also a clear dose response in this study. Moreover, the 
study incorporated an open-label comparison with tiotropium 
18 mcg once daily for 7 days. Although not truly a direct, 
blinded comparison, the results of Rennard et al24  suggested 
superior peak [area under the curve (AUC) at 0–4 hours post-
dose] and trough (AUC 22–24 hours postdose) FEV1 values 
for indacaterol 200 and 400 mcg on days 1 and 7. Similar 
observations were made in a study by Beier et al25 although 
the primary endpoint of this study was safety. Nevertheless, 
using indacaterol 400 or 800 mcg versus placebo over 
28 days’ treatment duration, Beier et al25 observed trough 
FEV1 improvements of 230 and 210 mL for 400 and 800 mcg, 
respectively, on day 14, and 220 and 210 mL for 400 and 
800 mcg, respectively, on day 28. Similar to observations in 
multiple-dose studies in asthmatics,18,26 there was no evidence 
of bronchodilator tolerance over the time period studied (up 
to 28 days).
Other endpoints
Particularly in COPD it is increasingly recognized that more 
patient-oriented clinical endpoints other than FEV1 are of 
vital importance in the long-term evaluation of COPD thera-
pies. These include quality of life, symptoms (eg, dyspnea), 
exacerbation rates, exercise tolerance and, finally, lung 
mechanics including static or dynamic hyperinflation.27 For 
most of these variables, no data for indacaterol have been 
published so far, but it is expected that these will be addressed 
in the ongoing phase III clinical development program.
There is, however, a single study investigating the effect 
of single-dose indacaterol 300 mcg versus formoterol 12 mcg 
twice daily and placebo on resting hyperinflation (inspira-
tory capacity) in patients with COPD. In the study by Pascoe 
et al28 indacaterol was superior to formoterol twice daily in 
improving FEV1 at 8 and 24 hours postdose, and also had 
marked superiority in improving resting inspiratory capacity 
at all time points between 4 and 24 hours postdose.28 These 
data support the concept of prolonged airway patency through 
sustained bronchodilation as an important factor reinforcing 
lung emptying and reduction of hyperinflation in COPD, 
as observed in studies with the once daily anticholinergic 
tiotropium.29
Safety and tolerability
Safety studies with indacaterol were designed to address 
typically anticipated class effects from beta agonists due to 
systemic absorption of drug, potentially leading to tachycar-
dia, palpitations, changes in etectrocardiogram parameters 
(eg, QT prolongation), tremor, hypokalemia, increase in Core Evidence 2009:4 40
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blood glucose levels, or headache. Three trials primarily 
evaluating safety and tolerability of indacaterol have been 
published, two in asthma,19,26 and one in COPD.25 All three 
trials incorporated a treatment duration of 28 days. In the 
studies by Yang et al and Beier et al indacaterol at once 
daily doses of 400 and 800 mcg SDDPI was used, whereas 
Chuchalin et al evaluated indacaterol at doses of 200, 400, 
or 600 mcg daily.
In all studies, the overall incidence of adverse events was 
similar for active treatment and placebo groups, and there 
was no dose-related increase in the incidence of adverse 
events. The most common adverse event associated with 
indacaterol use was cough, which was reported in 16.9% and 
15.3% of patients in the indacaterol 400 and 800 mcg groups, 
respectively, in the study by Yang et al26 in 8.1%, 17.1%, and 
10.3% of patients in the indacaterol 600, 400, and 200 mcg 
groups, respectively, in the study by Chuchalin et al19 and 
finally in 14.7% and 28.4% of patients in the 400 and 
800 mcg groups, respectively, in the study by Beier et al25 
This cough was, however, mild in severity, transient in nature 
and duration, and tended to decline with the duration of 
treatment. Further, treatment-associated cough did not lead 
to discontinuation of the study in any patients.
For the typical class effects of beta agonists, only modest 
effects were observed. While Yang et al26 reported small 
changes in postdose serum potassium and glucose levels of 
asthmatic patients exposed to indacaterol 400 or 800 mcg, no 
effect on these parameters was observed in the study by Beier 
et al25 using the same doses in COPD patients. However, in the 
study by Yang et al26 only few patients had potassium or glucose 
levels outside the normal range. In the study by Chuchalin et al19 
in asthmatics, no effect of once daily indacaterol 200, 400, and 
600 mcg on potassium and glucose levels was observed. In this 
study, there were also no changes in pulse rate, blood pressure, 
or mean QTc interval after 28 days’ exposure to indacaterol. 
However, there was a small, statistically significant increase 
of the QTc interval (8.9 ms) and pulse rate (4.9 beats per min) 
with the 800 mcg dose (n = 59) on day 28 in the study by Yang 
et al26 but these changes were numerically small and not clini-
cally significant. Again, none of these effects were observed 
by Beier et al25 in the study using indacaterol 400 and 800 mcg 
once daily in COPD patients.
Nevertheless, assuming that the doses of 400, 600, and 
800 mcg represent supratherapeutic doses (the selected 
dose for the phase III studies now appears to be 150 or 
300 mcg once daily), the overall safety data imply a 
favorable tolerability profile and a wide therapeutic window. 
This conclusion is also supported by data from a single-dose 
study using supratherapeutic doses of indacaterol, salbutamol, 
and salmeterol, demonstrating a good overall safety profile 
of indacaterol.20
Outcomes summary
Indacaterol is a novel once daily LABA developed for the 
treatment of obstructive airway disease, namely COPD and 
asthma. Clinical studies suggest that indacaterol produced 
rapid (within 5 min) and sustained (at least 24 hours) bron-
chodilation in patients with COPD and asthma of various 
severities. Exposure to a maximum of 28 days’ treatment with 
different doses of indacaterol confirmed the suitability of the 
drug for once daily dosing, with a favorable overall safety pro-
file, and lasting efficacy without evidence of development of 
tolerance. Early, open-label data indicate that indacaterol may 
be at least as effective as tiotropium in producing long-lasting 
bronchodilation. However, this needs to be investigated in 
well-controlled, fully blinded clinical trials. Interpretation 
of clinical data of indacaterol in asthma and COPD is some-
what complicated by the fact that several doses and different 
devices were studied (MDI, SDDPI, MDDPI). At present, the 
clinical trail registry lists the majority of ongoing studies with 
indacaterol at doses of 150 or 300 mcg once daily delivered 
by dry powder inhaler. Thus, it is anticipated that these doses 
will represent the marketed doses.
Clearly, there is more prospect for indacaterol monotherapy in 
COPD, where antiinflammatory treatment is not fully established 
and – in contrast to the ongoing discussion in asthma – issues 
about a potential risk of LABA use causing excess mortality have 
not been raised. In addition, indacaterol represents an attractive 
partner agent for future combination therapies, for example once 
daily fixed combination with an inhaled corticosteroid for both 
asthma and COPD, with an inhaled once daily anticholinergic 
bronchodilator in COPD (eg, “super”-Combivent™), or even in a 
triple combination with an inhaled corticosteroid and long-acting 
anticholinergic for COPD.
However, more data are required, particularily in COPD, 
to fully assess the therapeutic potential of indacaterol in 
improving symptoms, quality of life, exacerbation rates, 
disease progression, excercise capacity, and hyperinflation. 
The currently ongoing phase III clinical trial program will 
add knowledge in respect to many long-term efficacy out-
comes and gather further safety and tolerability data in both 
asthma and COPD.
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